Target intelligence / Profile preview

Glutamate ionotropic receptor (iGluR)

Target
iGluR
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Tetrameric protein complex
01

Overview

Glutamate ionotropic receptors (iGluRs) are tetrameric ligand-gated ion channels present throughout the nervous system, responsible for the majority of fast excitatory neurotransmission. They are activated by glutamate and sub-divided into AMPA, NMDA, kainate, and delta classes based on their pharmacology and sequence similarities. Each receptor subunit contains modular domains: the extracellular amino-terminal domain (ATD), the ligand-binding domain (LBD), the transmembrane ion channel-forming domain (TMD), and the intracellular carboxy-terminal domain (CTD). iGluRs mediate synaptic signaling and plasticity, which is crucial for learning and memory. Genetic and pharmacological evidence implicates iGluRs in a wide range of CNS diseases. Drugs targeting iGluRs are in clinical use for neurological and psychiatric disorders, but therapeutic manipulation is limited by significant safety concerns, including neurotoxicity and cognitive side effects.

Other names
Ionotropic glutamate receptoriGluRGlutamate-gated ion channelAMPA receptor (subtype)NMDA receptor (subtype)Kainate receptor (subtype)Delta receptor (subtype)
02

Mechanism of action

Antagonism/inhibition (block ion channel to reduce excitatory neurotransmission); Allosteric modulation (Increase or decrease receptor function via non-competitive sites); Channel blocking (e.g., Mg(^2+) block in NMDA receptors); Positive or negative modulation (e.g., promoting or inhibiting receptor opening)

03

Biological functions

Signal transductionFast excitatory synaptic transmissionSynaptic plasticityRegulation of neuronal excitabilityLearning and memory
04

Disease associations

Neurodegenerative diseaseEpilepsySchizophreniaIschemia (stroke)Chronic painMood disordersAlcoholismOther CNS disorders
05

Safety considerations

NeurotoxicityPsychotropic side effectsExcitotoxicitySeizures
06

Interacting drugs

Memantine

7 more in the full profile.

Beyond the preview

Go deeper on Glutamate ionotropic receptor (iGluR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate ionotropic receptor (iGluR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call